Phaseline

Targets › SLC6A2

SLC6A2 (Sodium-dependent noradrenaline transporter): drug programs, companies and trials

89 programs from 72 companies in 177 trials: 67 Phase 2, 53 Phase 4, 31 Phase 3, 26 Phase 1; Psychiatry, Other, Oncology; next expected readout Nov 2026.

Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). (UniProt, P23975)

Open in Phaseline: the race on SLC6A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of PennsylvaniaVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Posttraumatic Stress DisorderNov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
All India Institute of Medical Sciences, BhubaneswarDosulepin
Tricyclic antidepressant with serotonin and norepinephrine reuptake inhibition
SLC6A4, SLC6A2Phase 4Somatic Symptom Disorder (DSM-V)Nov 2026
All India Institute of Medical Sciences, BhubaneswarVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Somatic Symptom Disorder (DSM-V)Nov 2026
University of MiamiDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4THADec 2026
Rochester Center for Behavioral MedicineDyanavel XR
Amphetamine derivative; CNS stimulant that increases dopamine and norepinephrine release
SLC6A2, SLC6A3Phase 4FatigueDec 2026
Daniel CouryAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4ADHDJan 2027
Daniel CouryMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHDJan 2027
Matthew J O'Brien, PhD, BCBA-DAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity DisorderMar 2027
Donald Gilbert, MD, MS, FAAN, FAAPMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity Disorder CombinedMar 2027
VA Office of Research and DevelopmentMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Posttraumatic Stress Disorder (PTSD); EpilepsyMar 2027
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Reduced noradrenaline by using a lower MAP target (≥55 mmHg)
Noradrenaline reuptake inhibition via sympathomimetic vasopressor effect
SLC6A2Phase 4Cardiogenic ShockApr 2027
David SteffensDesvenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Major Depressive DisorderApr 2027
Wake Forest University Health SciencesDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Depression; Depression in Old AgeMay 2027
Montefiore Medical CenterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Back Pain, LowMay 2027
Sunnybrook Health Sciences CentreDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee OsteoarthritisJul 2027
Dar Clinical Research Inc.Methylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity DisorderJul 2027
University of California, IrvinePhentermine
Norepinephrine transporter releasing agent
SLC6A2Phase 4ObesityJul 2027
The Chaim Sheba Medical Centermethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Velocardiofacial SyndromeAug 2027
Aarhus University HospitalDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Functional DisorderNov 2027
Axsome TherapeuticsBupropion (AXS-05)
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma …Dec 2027
University of California, Irvinenortriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4MénièreDec 2027
Supernus PharmaceuticalsViloxazine Hydrochloride (SPN-812)
Norepinephrine transporter inhibitor
SLC6A2Phase 4Attention-Deficit/Hyperactivity DisorderJan 2028
Northwestern UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee OsteoarthritisMar 2028
Johns Hopkins UniversityMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHD - Combined TypeNov 2028
Benedict AlterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 4Knee Osteoarthritis (Knee OA)Dec 2028
Currax PharmaceuticalsBupropion
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ObesityJan 2029
The Cleveland ClinicPhentermine
Norepinephrine transporter releasing agent
SLC6A2Phase 4Liver CirrhosesFeb 2029
VA Office of Research and DevelopmentAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 4Posttraumatic Stress Disorder With Attention DeficJun 2029
University of ArizonaAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 4Obstructive Sleep Apnea (OSA); Obstructive Sleep ApneaJan 2030
Gagan JoshiAmphetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent
SLC6A3, SLC6A2Phase 4Attention Deficit Hyperactivity Disorder (ADHD)Feb 2030
Children's Hospital Medical Center, CincinnatiMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention-Deficit/Hyperactivity Disorder (ADHD)Feb 2030
Sairam ParthasarathyAtomoxetine-oxybutynin
Norepinephrine reuptake inhibitor combined with muscarinic-3 receptor antagonist to increa
SLC6A2, CHRM3Phase 4Obstructive Sleep Apnea (OSA)Mar 2030
Hospital de Clinicas de Porto AlegreMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention Deficit Disorder With HyperactivityDec 2032
The Royal's Institute of Mental Health ResearchContrave
Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop
OPRM1, SLC6A2, SLC6A3Phase 4Obesity–
NYU Langone HealthMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Attention-deficit/Hyperactivity Disorder–
Florida International UniversityMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ADHD–
Iuliu Hatieganu University of Medicine and PharmacyNefopam
Non-opioid analgesic; mechanism includes monoamine reuptake inhibition and NMDA receptor a
SLC6A2, SLC6A3, GRIN1Phase 4Pancreatoduodenectomy–
Axsome TherapeuticsSolriamfetol Dose A
Dopamine and norepinephrine reuptake inhibitor
SLC6A3, SLC6A2Phase 3Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsDec 2026
Parc de Salut MarDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Chronic Post-surgical PainDec 2026
M.D. Anderson Cancer CenterMethylphenidate Hydrochloride
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Advanced Malignant Neoplasm; Sleep; Prostate Cancer; Prostate Carcinoma …Dec 2026
University Hospital, Strasbourg, FranceMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Adult ADHDMay 2027
Tanta UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Biliary DiseaseJun 2027
Radboud University Medical CenterAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 3Parkinson's Disease (PD)Jul 2027
OtsukaCentanafadine (EB-1020)
Monoamine transporter inhibitor
SLC6A4, SLC6A3, SLC6A2Phase 3Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD)Aug 2027
Theravance BiopharmaAmpreloxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 3Symptomatic Neurogenic Orthostatic HypotensionJan 2028
Axsome TherapeuticsEsreboxetine (AXS-14)
Norepinephrine transporter inhibitor
SLC6A2Phase 3FibromyalgiaMar 2028
Dr. Inge WinterVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Bipolar DepressionJun 2028
Reinier de Graaf GroepVenlafaxine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 3Breast CancerJan 2029
Odense University HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Brain Tumor, PediatricDec 2029
Children's Oncology GroupIobenguane I 131 (I-131)
Norepinephrine transporter substrate
SLC6A2Phase 3GanglioneuroblastomaSep 2030
University College, LondonAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 3Alzheimer's Disease (AD)Mar 2031
Vrije Universiteit BrusselMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 3Fatigue–
Vrije Universiteit BrusselReboxetine
Noradrenaline reuptake inhibitor
SLC6A2Phase 3Fatigue–
Seattle Children's HospitalPhentermine
Norepinephrine transporter releasing agent
SLC6A2Phase 2Hypothalamic ObesityNov 2026
Wright State UniversityImipramine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Rosacea; Photosensitivity; ImipramineDec 2026
University of HaifaReboxetine
Noradrenaline reuptake inhibitor
SLC6A2Phase 2Posttraumatic Stress Disorder; PTSDDec 2026
University of Haifamethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Posttraumatic Stress Disorder; PTSDDec 2026
Mayo ClinicAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Interstitial Lung Disease; Refractory Chronic CoughDec 2026
Polyclinique de l'EuropeAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Inflammatory Bowel DiseasesDec 2026
M.D. Anderson Cancer CenterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Chemotherapy-Induced Peripheral NeuropathyDec 2026
Alliance for Clinical Trials in OncologyDuloxetine Hydrochloride
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Stage II Colorectal Cancer AJCC v8Dec 2026
University of PennsylvaniaDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Inflammatory Bowel DiseasesMar 2027
RemedyMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Post Traumatic Stress DisorderMar 2027
Memorial Sloan Kettering Cancer Centeriobenguane I 131
Radioactive iodine-131 targeted to norepinephrine transporters
SLC6A2Phase 2NeuroblastomaMay 2027
Yan Yang, MD, Ph.DDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Chemotherapy-induced Peripheral NeuropathyJul 2027
Definium Therapeutics USMidomafetamine (DT402)
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Autism Spectrum DisorderAug 2027
Sunnybrook Health Sciences CentreMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Alzheimer s DiseaseOct 2027
Medical University of LodzLisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Attention Deficit Disorder with HyperactivityDec 2027
Medical University of LodzMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Attention Deficit Disorder with HyperactivityDec 2027
Centre hospitalier de l'Université de Montréal (CHUM)Lisdexamfetamine
Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor
SLC6A3, SLC6A2, SLC18A2Phase 2Methamphetamine AbuseDec 2027
University of RochesterMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 2Chronic PainDec 2027
Russell McCulloh, MDPhentermine
Norepinephrine transporter releasing agent
SLC6A2Phase 2Childhood ObesityJan 2028
Icahn School of Medicine at Mount SinaiAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 2Melanocortin Obesity SyndromeMar 2028
Prof. Dr. Frank BehrensDEX IR tablets
Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin
SLC6A3, SLC6A2Phase 2Attention-Deficit/Hyperactivity Disorder (ADHD)Mar 2028
Prof. Dr. Frank BehrensDEX XL
Sympathomimetic amine; inhibits reuptake of dopamine and noradrenaline; increases monoamin
SLC6A3, SLC6A2Phase 2Attention-Deficit/Hyperactivity Disorder (ADHD)Mar 2028
University of RochesterDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Painful Peripheral NeuropathyJun 2028
Wright State UniversityAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2RosaceaDec 2028
University of MichiganAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Quiescent Crohn's Disease (CD)Dec 2029
Md. Moktadirul Hoque ShuvoAmitriptyline
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 2Functional Dyspepsia–
First Affiliated Hospital of Chongqing Medical UniversityDuloxetine
Serotonin transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A4, SLC6A2Phase 1DepressionDec 2026
Brigham and Women's Hospital[C-11]Methylreboxetine ([C-11]MRB)
Norepinephrine transporter (NET) radioligand for PET imaging
SLC6A2Phase 1Multiple SclerosisDec 2026
Resilient PharmaceuticalsMidomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 1Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder …Feb 2027
St. Jude Children's Research HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 1Sickle Cell DiseaseJul 2027
Brigham and Women's HospitalAtomoxetine-plus-oxybutynin (AtoOxy)
Norepinephrine reuptake inhibitor combined with muscarinic antagonist to activate pharynge
SLC6A2, CHRM1Phase 1Obstructive Sleep ApneaSep 2028
Rachel YehudaMDMA Hydrochloride
Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion
SLC6A4, SLC6A2, SLC6A3Phase 1Mental WellbeingSep 2029
Satish R. RajAtomoxetine
Norepinephrine transporter inhibitor
SLC6A2Phase 1TachycardiaDec 2029
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)[18F]-6F-DA
Fluorine-18 labeled dopamine analog entering cells via norepinephrine transporter (NET) an
SLC6A2, SLC18A1Phase 1PheochromocytomaNov 2048
Massachusetts General HospitalMethylphenidate
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 1Brain Injury Traumatic Severe (Diagnosis)–

Conditions

Obstructive Sleep Apnea (6) Post Traumatic Stress Disorder (6) Posttraumatic Stress Disorder (5) ADHD (5) Prostate Cancer (3) Obesity (3) Multiple Sclerosis (3) Attention Deficit Hyperactivity Disorder (ADHD) (3) PTSD (3) Major Depressive Disorder (3) Attention-Deficit/Hyperactivity Disorder (ADHD) (3) Schizophrenia (3)

Modalities

small molecule (80), protein or peptide (5), mixed (3)

Companies

Brigham and Women's Hospital (3) Axsome Therapeutics (3) University of Pennsylvania (2) Wright State University (2) University of Rochester (2) VA Office of Research and Development (2) M.D. Anderson Cancer Center (2) University of Haifa (2) Medical University of Lodz (2) Sunnybrook Health Sciences Centre (2) University of California, Irvine (2) All India Institute of Medical Sciences, Bhubaneswar (2) Daniel Coury (2) Vrije Universiteit Brussel (2) Prof. Dr. Frank Behrens (2) Aarhus University Hospital (1) Johns Hopkins University (1) Parc de Salut Mar (1) First Affiliated Hospital of Chongqing Medical University (1) Rachel Yehuda (1)

Related targets

SLC6A3 (38) SLC6A4 (34) OPRM1 (2) SLC18A2 (2) GRIN1 (1) SLC18A1 (1) SLC5A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) NR3C2 (1) AGTR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.